- Conditions
- Type 2 Diabetes, Ketone Body Metabolism, Ketones, Metabolism
- Interventions
- Ketone Ester Acute, Placebo Acute
- Dietary Supplement
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 609
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Heart Failure
- Interventions
- CASA Intervention
- Other
- Lead sponsor
- Denver Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Dyslipidemia, Obesity
- Interventions
- Freeze-dried strawberries, Dietary fiber
- Dietary Supplement
- Lead sponsor
- Oklahoma State University
- Other
- Eligibility
- 19 Years to 72 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Stillwater, Oklahoma
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes
- Interventions
- Home care telemedicine
- Procedure
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2004
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Indianapolis, Nebraska
- Conditions
- Hypertension in Pregnancy, Gestational Hypertension, Preeclampsia, Chronic Hypertension With Pre-Eclampsia, Eclampsia, Chronic Hypertension in Obstetric Context
- Interventions
- virtual cardiac wellness program, Placebo comparator
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
- Interventions
- Med AAAction intervention
- Other
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Knoxville, Tennessee • Memphis, Tennessee
- Conditions
- Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
- Interventions
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Procedure
- Lead sponsor
- AngioInsight
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
- Conditions
- Heart Failure, Copd, Liver Failure, Diabetes Mellitus, Cancer, End Stage Renal Disease
- Interventions
- Medically Tailored Meals
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Lafayette, Colorado
- Conditions
- Hypertension, Chronic Stable Angina, Vasospastic Angina
- Interventions
- Amlodipine
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Heart Failure, Congestive
- Interventions
- OPTIMIZER System
- Device
- Lead sponsor
- Impulse Dynamics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 1
- States / cities
- Orangeburg, New York
- Conditions
- Stress Disorders, Post-traumatic
- Interventions
- Trauma Center Trauma Sensitive Yoga Intervention (TCTSY), Cognitive Processing Therapy
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Decatur, Georgia • Portland, Oregon
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
- Interventions
- ATI-5923, Coumadin (warfarin)
- Drug
- Lead sponsor
- ARYx Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
- Conditions
- Heart Failure
- Interventions
- CardioPumlonary Management System
- Device
- Lead sponsor
- Analog Device, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Palm Springs, California • Miami, Florida • Orlando, Florida + 4 more
- Conditions
- Heart Failure, Congestive, Pulmonary Disease, Chronic Obstructive, Depression, Anxiety
- Interventions
- ACCES - Adjusting to Chronic Conditions with Education and Support
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heart Failure
- Interventions
- Text4HF, MyApps, MyApps & Text4HF, Enhanced Usual Care
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Heart Failure, Heart Decompensation
- Interventions
- Cinaciguat (BAY58-2667), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Detroit, Michigan • Cincinnati, Ohio + 3 more
- Conditions
- Acute Myocardial Infraction or Chest Pain, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), Diabetes, Pneumonia
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Myeloid Sarcoma, Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
- Interventions
- Cladribine, Cytarabine, Dexrazoxane Hydrochloride, Gemtuzumab Ozogamicin, Idarubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- Tiotropium, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cancer, Chronic Stress, Autonomic Dysfunction
- Interventions
- Hight intensity interval training, Cyclic Hyperventilation with Retention
- Behavioral
- Lead sponsor
- University of Northern Colorado
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Greeley, Colorado
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy, Hyperinsulinemic Hypoglycemia, Familial 1, Diabetes Mellitus, Adrenoleukodystrophy, Neonatal, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Beta-ketothiolase Deficiency, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Primary Hyperoxaluria Type 1, Congenital Bile Acid Synthesis Defect Type 2, Pyridoxine-Dependent Epilepsy, Hereditary Fructose Intolerance, Hypophosphatasia, Hyperargininemia, Mucopolysaccharidosis Type 6, Argininosuccinic Aciduria, Citrullinemia, Type I, Wilson Disease, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Biotinidase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Intrinsic Factor Deficiency, Usher Syndrome Type 1D/F Digenic (Diagnosis), Cystic Fibrosis, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Cystinosis, Chronic Granulomatous Disease, Cerebrotendinous Xanthomatoses, Maple Syrup Urine Disease, Type 2, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Thyroid Dyshormonogenesis 6, Thyroid Dyshormonogenesis 5, Supravalvar Aortic Stenosis, Factor X Deficiency, Hemophilia A, Hemophilia B, Tyrosinemia, Type I, Fructose 1,6 Bisphosphatase Deficiency, Glycogen Storage Disease Type I, G6PD Deficiency, Glycogen Storage Disease II, Galactokinase Deficiency, Mucopolysaccharidosis Type IV A, Galactosemias, Guanidinoacetate Methyltransferase Deficiency, Agat Deficiency, Glutaryl-CoA Dehydrogenase Deficiency, Gtp Cyclohydrolase I Deficiency, Hyperinsulinism-Hyperammonemia Syndrome, Primary Hyperoxaluria Type 2, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Mitochondrial Trifunctional Protein Deficiency, Sickle Cell Disease, Beta-Thalassemia, Holocarboxylase Synthetase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, Primary Hyperoxaluria Type 3, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Apparent Mineralocorticoid Excess, HSDB, CBAS1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 1, Severe Combined Immunodeficiency, X Linked, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Diabetes Mellitus, Permanent Neonatal, Isovaleric Acidemia, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Jervell and Lange-Nielsen Syndrome 2, Hyperinsulinemic Hypoglycemia, Familial, 2, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Jervell and Lange-Nielsen Syndrome 1, Lysosomal Acid Lipase Deficiency, CblF, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, Waardenburg Syndrome Type 2A, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Methylmalonic Aciduria and Homocystinuria Type cblC, MAHCD, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Congenital Disorder of Glycosylation Type 1B, Mthfr Deficiency, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Usher Syndrome, Type 1B, N-acetylglutamate Synthase Deficiency, Ornithine Transcarbamylase Deficiency, Phenylketonurias, Waardenburg Syndrome Type 1, Congenital Hypothyroidism, Propionic Acidemia, Usher Syndrome, Type 1F, Pancreatic Agenesis 1, Hereditary Hypophosphatemic Rickets, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, MOWS, Epilepsy, Early-Onset, Vitamin B6-Dependent, Pyridoxal Phosphate-Responsive Seizures, Pituitary Hormone Deficiency, Combined, 1, Ptsd, Dihydropteridine Reductase Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Retinoblastoma, Multiple Endocrine Neoplasia Type 2B, Pseudohypoaldosteronism, Type I, Liddle Syndrome, Biotin-Responsive Basal Ganglia Disease, SCD, DIAR1, GSD1C, Acrodermatitis Enteropathica, Thyroid Dyshormonogenesis 1, Riboflavin Transporter Deficiency, Waardenburg Syndrome, Type 2E, SRD, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Barth Syndrome, Adrenocorticotropic Hormone Deficiency, Transcobalamin II Deficiency, Thyroid Dyshormonogenesis 3, Segawa Syndrome, Autosomal Recessive, Autosomal Recessive Nonsyndromic Hearing Loss, Thyroid Dyshormonogenesis 2A, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Hypothyroidism Due to TSH Receptor Mutations, Usher Syndrome Type 1C, Usher Syndrome Type 1G (Diagnosis), Von Willebrand Disease, Type 3, Combined Immunodeficiency Due to ZAP70 Deficiency, Adenine Phosphoribosyltransferase Deficiency, Metachromatic Leukodystrophy, Canavan Disease, Menkes Disease, Carbonic Anhydrase VA Deficiency, Developmental and Epileptic Encephalopathy 2, 17 Alpha-Hydroxylase Deficiency, Smith-Lemli-Opitz Syndrome, Krabbe Disease, Glutathione Synthetase Deficiency, Mucopolysaccharidosis Type 7, Rett Syndrome, Molybdenum Cofactor Deficiency, Type A, Niemann-Pick Disease, Type C1, Niemann-Pick Disease Type C2, Ornithine Aminotransferase Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Leber Congenital Amaurosis 2, Dravet Syndrome, Mucopolysaccharidosis Type 3 A, Ornithine Translocase Deficiency, Carnitine-acylcarnitine Translocase Deficiency, Glucose Transporter Type 1 Deficiency Syndrome, Creatine Transporter Deficiency, Niemann-Pick Disease Type A, Pitt Hopkins Syndrome, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Ataxia With Isolated Vitamin E Deficiency, Angelman Syndrome, Prader-Willi Syndrome, Homocystinuria, Permanent Neonatal Diabetes Mellitus, Transient Neonatal Diabetes Mellitus, Factor VII Deficiency, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Glycogen Storage Disease IC, Glycogen Storage Disease Type IB, Central Hypoventilation Syndrome With or Without Hirschsprung Disease
- Interventions
- Confirmatory Testing
- Diagnostic Test
- Lead sponsor
- RTI International
- Other
- Eligibility
- 1 Day to 31 Days
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Chronic Heart Failure, Chronic Obstructive Pulmonary Disorder
- Interventions
- BOOST High Protein
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Heart Failure With Reduced Ejection Fraction, Nonischemic Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- End Stage Renal Disease
- Interventions
- Not listed
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington